Clinical trials recruiting for Solid Tumor
74
Recruiting trials
39
US states with sites
33
Countries
3%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Nivolumab | 4 |
| Pembrolizumab | 4 |
| Bevacizumab | 3 |
| Docetaxel | 3 |
| Abemaciclib | 2 |
| BL-B01D1 | 2 |
| BL-M17D1 | 2 |
| Cetuximab | 2 |
| GNC-077 | 2 |
| Panitumumab | 2 |
| Prednisone | 2 |
| 18F-TRX | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Texas | 23 |
| New York | 17 |
| California | 16 |
| Florida | 16 |
| Tennessee | 16 |
| Massachusetts | 15 |
| Virginia | 15 |
| Ohio | 14 |
| Arizona | 11 |
| Colorado | 11 |
| New Jersey | 10 |
| Illinois | 9 |
Top cities
Nashville, Tennessee 15Boston, Massachusetts 14New York, New York 14Fairfax, Virginia 11Houston, Texas 11Dallas, Texas 9Los Angeles, California 9Chicago, Illinois 8San Antonio, Texas 8San Francisco, California 7
Self-screener
Recruiting trials
- A Beta-only IL-2 ImmunoTherapY Study
- A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
- A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
- A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
- A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
- A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors
- A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
- A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
- A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
- A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
- A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
- A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
- A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
- A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
- A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
- A Study of GC203 TIL in Advanced Malignant Solid Tumors
- A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
- A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors
- A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
- A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
- A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- A Study of TRK-950 in Patients With Advanced Solid Tumors
- A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
- A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
- A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
- Brodalumab in the Treatment of Immune-Related Adverse Events
- Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer
- DESCANSO, a Mental Health Intervention for Depression, Insomnia, and Fatigue Symptoms in Latino People With Cancer
- Dabrafenib and/or Trametinib Rollover Study
- Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
- Effects of Neoadjuvant Prehabilitation on Post-Interventional Physical and Psychological Outcomes in Oncology Patients With Solid Tumors
- FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
- FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Imaging of Solid Tumors Using 18F-TRX
- Indocyanine Green (ICG) Guided Tumor Resection
- Interest of Medical Hypnosis in Anxious Patients Treated by Radiotherapy
- Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
- Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
- MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
- Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)
- Methylation Profile Test (Methylscape) in Body Fluids for Multi-Cancer Detection and Monitoring in Colombia
- Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
- Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI
- PET-imaging of Two Vartumabs in Patients With Solid Tumors
- PRE-ISPY Phase I/II Oncology Platform Program
- Personalised Immunotherapy Platform
- Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
- Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors
- Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
- Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
- Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
- R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
- RAPA-201 Therapy of Solid Tumors
- SMP-3124LP in Adults With Advanced Solid Tumors
- Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
- Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
- Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
- Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
- Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
- Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
- Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
- Trop2-targeted immunoPET Imaging of Solid Tumors
Related conditions
Trials recruiting for Solid Tumor often also study these conditions. Each links to its own recruiting-trial list.
Lung cancer 2180Breast cancer 2239Colorectal cancer 1359Non-small cell lung cancer 507Pancreatic cancer 870Melanoma 487Prostate cancer 1234Gastric cancer 91Ovarian cancer 118Head and neck cancer 62
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Solid Tumor trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.